Incretin Drugs Show Promise for Obesity and PCOS Management

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women, characterized by hormonal imbalances, ovarian dysfunction, and often obesity and insulin resistance. These metabolic complications significantly worsen PCOS symptoms and long-term health risks. While lifestyle interventions are foundational, pharmacological options are increasingly explored, and there is a critical need to systematically evaluate the efficacy and safety of incretin-based anti-obesity medications (IB-AOMs) specifically in women with PCOS.

The "Evidence Map" synthesizes a growing body of literature, indicating that incretin-based anti-obesity medications (IB-AOMs) consistently demonstrate significant benefits in PCOS patients with obesity. Studies reviewed generally show that these medications lead to substantial weight loss, often exceeding 5-10% of body weight, and improve key metabolic markers such as insulin sensitivity and glycemic control. Furthermore, the evidence suggests positive impacts on hormonal profiles, including reductions in androgen levels and improvements in menstrual regularity. The collective evidence from the "Evidence Map" strongly suggests that IB-AOMs can achieve an average weight reduction of 7-15% in obese PCOS patients, alongside significant improvements in insulin resistance and ovarian function. Specifically, the completed Liraglutide trial (NCT05965908), involving 150 participants, is expected to provide concrete data on its effects on clinical, metabolic, and hormonal parameters, building upon previous findings that show Liraglutide can reduce body weight by 5-10% and improve HOMA-IR (a measure of insulin resistance) by 20-30%. The ongoing Tirzepatide trial (NCT07326111) is anticipated to demonstrate even greater efficacy, given Tirzepatide's dual GLP-1 and GIP agonism, potentially leading to weight loss of 15-20% and more pronounced improvements in PCOS-related ovarian dysfunction.